1. Scrip
  2. >>Therapy Areas

Novartis Hit By Canakinumab NSCLC Miss

Interleukin-1 Beta Inhibitor Fails To Improve Survival

 
• By Kevin Grogan

The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.

dart
CANOPY-2 misses the target • Source: Shutterstock

Having failed to add a cardiovascular indication for canakinumab, Novartis AG's hopes of progressing the anti-inflammatory agent in oncology have been hit by another failure, this time in a late-stage trial for non-small cell lung cancer (NSCLC).

The Swiss major has revealed that canakinumab in combination with the chemotherapy agent docetaxel did not meet the primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial